Mölnlycke Health Care — Cyborg Score 7/10

Strong
Medical wound care and surgical supplies

Strategic Profile

Investor AB acquired Mölnlycke in 2007, and Mölnlycke is the largest wholly-owned subsidiary within Patricia Industries. As of May 2026, Mölnlycke formed a joint venture with Zhende Medical in China (majority-owned by Mölnlycke) to integrate wound care portfolios and accelerate growth in one of the world's fastest-growing wound care markets.

Cyborg Score Rationale

Mölnlycke demonstrates strong strategic execution through geographic expansion, strategic partnerships, and continuous innovation. Recent manufacturing investments and a joint venture in fast-growing markets signal confidence in growth trajectory. Leadership transitions (March 2026 CEO resignation) and CFO appointment changes warrant monitoring but appear operational.

Top Insights

  • In June 2026, Mölnlycke confirmed approximately EUR 40 million in combined investments in manufacturing facilities in Mikkeli, Finland and Oldham, UK to increase capacity and enhance supply chain resilience.
  • In 2024, Antiseptics delivered 23% organic growth and Wound Care reached over EUR 1.2 billion in sales.
  • Mölnlycke operates across four primary business areas: Wound Care, Operating Room Solutions, Gloves, and Antiseptics.
  • The company has 8,617 total employees.

Named Competitors

  • Avanos Medical Products — Surgical and wound care products
  • TIDI Products — Infection prevention and single-use surgical supplies
  • Urgo Medical — Wound care and skin health solutions
  • Lohmann & Rauscher — Wound care and medical compression products

Recent Developments

  • (June 2026) Board changes announced: Filippa Stenberg appointed as board member, Christian Cederholm departing
  • (June 2026) EUR 40 million combined manufacturing investment in Finland and UK to strengthen global wound care network
  • (May 2026) Joint venture formed with Zhende Medical in China to accelerate growth in Chinese wound care market
  • (April 2026) Andreas Johansson appointed as Interim Chief Financial Officer
  • (March 2026) CEO Zlatko Rihter resigned; Guillaume Joucla (CFO) appointed interim CEO

Open the full interactive Mölnlycke Health Care report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →